Teva Set For Immediate US Launch Of Austedo In Tardive Dyskinesia
Executive Summary
FDA-approved labeling includes boxed warning for depression and suicidality, though this is specific for Huntington's disease patients, who are prone to these conditions.
You may also be interested in...
Nuvelution Puts Business Model Into Action With Teva/Austedo Deal
Focused on drug development risk-sharing partnerships, Nuvelution signs its first partnership, with Teva, to conduct Phase III development of recently approved Austedo for pediatric Tourette syndrome.
Teva Lands A CEO: Can Schultz Replicate Lundbeck Success?
After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.
Teva Lands A CEO: Can Schultz Replicate Lundbeck Success?
After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.